Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney

Objective To retrospectively evaluate early clinical outcomes of percutaneous microwave ablation (MWA) for stage T1a renal cell carcinomas (RCCs) in solitary kidney patients. Materials and methods 15 solitary kidney patients with 16 stage T1a N0M0 biopsy-proved RCCs underwent CT-guided percutaneous...

Full description

Bibliographic Details
Main Authors: Hong Meng, Huan Yang, Haipeng Jia, Fengmin Pan, Xinzhe Dong, Bo Liu, Chunhai Li
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:International Journal of Hyperthermia
Subjects:
Online Access:http://dx.doi.org/10.1080/02656736.2021.1915503
_version_ 1819319824948396032
author Hong Meng
Huan Yang
Haipeng Jia
Fengmin Pan
Xinzhe Dong
Bo Liu
Chunhai Li
author_facet Hong Meng
Huan Yang
Haipeng Jia
Fengmin Pan
Xinzhe Dong
Bo Liu
Chunhai Li
author_sort Hong Meng
collection DOAJ
description Objective To retrospectively evaluate early clinical outcomes of percutaneous microwave ablation (MWA) for stage T1a renal cell carcinomas (RCCs) in solitary kidney patients. Materials and methods 15 solitary kidney patients with 16 stage T1a N0M0 biopsy-proved RCCs underwent CT-guided percutaneous microwave ablation between October 2016 and July 2020. The patients were followed up with contrast-enhanced computed tomography or magnetic resonance imaging at 1, 3, and 6 months and every 6 months thereafter. Serum creatinine levels of each patient pre MWA, 1 day after MWA and the most recent record were collected. Technical effectiveness, local recurrence, survival rates and complications were accessed. Results Complete ablation was achieved in all 16 tumors (100%) including 13 clear cell carcinomas and 3 papillary carcinomas. Within the follow-up time (median: 24 months) no tumor recurrence or major complication was detected. No significant change in serum creatinine level was noted. The cancer-specific survival rate was 100% (15 of 15), and 1-, 2-, and 3-year overall survival rates were 100%, 93.3%, and 93.3%, respectively. Conclusion Percutaneous MWA is an effective and safe treatment option for stage T1a RCCs in solitary kidney patients; it can achieve high complete ablation rate in selected lesions of appropriate size and location.
first_indexed 2024-12-24T11:09:50Z
format Article
id doaj.art-7b7c2f6e793347b3b86f81ef4bde34dd
institution Directory Open Access Journal
issn 0265-6736
1464-5157
language English
last_indexed 2024-12-24T11:09:50Z
publishDate 2021-01-01
publisher Taylor & Francis Group
record_format Article
series International Journal of Hyperthermia
spelling doaj.art-7b7c2f6e793347b3b86f81ef4bde34dd2022-12-21T16:58:32ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572021-01-0138169169510.1080/02656736.2021.19155031915503Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidneyHong Meng0Huan Yang1Haipeng Jia2Fengmin Pan3Xinzhe Dong4Bo Liu5Chunhai Li6Qilu Hospital of Shandong UniversityShandong Provincial Hospital affiliated to Shandong First Medical CollegeQilu Hospital of Shandong UniversityQilu Hospital of Shandong UniversityQilu Hospital of Shandong UniversityQilu Hospital of Shandong UniversityQilu Hospital of Shandong UniversityObjective To retrospectively evaluate early clinical outcomes of percutaneous microwave ablation (MWA) for stage T1a renal cell carcinomas (RCCs) in solitary kidney patients. Materials and methods 15 solitary kidney patients with 16 stage T1a N0M0 biopsy-proved RCCs underwent CT-guided percutaneous microwave ablation between October 2016 and July 2020. The patients were followed up with contrast-enhanced computed tomography or magnetic resonance imaging at 1, 3, and 6 months and every 6 months thereafter. Serum creatinine levels of each patient pre MWA, 1 day after MWA and the most recent record were collected. Technical effectiveness, local recurrence, survival rates and complications were accessed. Results Complete ablation was achieved in all 16 tumors (100%) including 13 clear cell carcinomas and 3 papillary carcinomas. Within the follow-up time (median: 24 months) no tumor recurrence or major complication was detected. No significant change in serum creatinine level was noted. The cancer-specific survival rate was 100% (15 of 15), and 1-, 2-, and 3-year overall survival rates were 100%, 93.3%, and 93.3%, respectively. Conclusion Percutaneous MWA is an effective and safe treatment option for stage T1a RCCs in solitary kidney patients; it can achieve high complete ablation rate in selected lesions of appropriate size and location.http://dx.doi.org/10.1080/02656736.2021.1915503microwave ablationrenal cell carcinomasolitary kidneyrenal functionsafety
spellingShingle Hong Meng
Huan Yang
Haipeng Jia
Fengmin Pan
Xinzhe Dong
Bo Liu
Chunhai Li
Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney
International Journal of Hyperthermia
microwave ablation
renal cell carcinoma
solitary kidney
renal function
safety
title Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney
title_full Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney
title_fullStr Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney
title_full_unstemmed Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney
title_short Efficacy and safety of CT-guided microwave ablation for stage T1a renal cell carcinoma in patients with a solitary kidney
title_sort efficacy and safety of ct guided microwave ablation for stage t1a renal cell carcinoma in patients with a solitary kidney
topic microwave ablation
renal cell carcinoma
solitary kidney
renal function
safety
url http://dx.doi.org/10.1080/02656736.2021.1915503
work_keys_str_mv AT hongmeng efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney
AT huanyang efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney
AT haipengjia efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney
AT fengminpan efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney
AT xinzhedong efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney
AT boliu efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney
AT chunhaili efficacyandsafetyofctguidedmicrowaveablationforstaget1arenalcellcarcinomainpatientswithasolitarykidney